Google
IVA 株価分析 — INVENTIVA SA (Healthcare >> Biotechnology)
IVA に関するよくある質問
IVAのROE（自己資本利益率）は？
INVENTIVA SAのROEは2,290.08%です。
IVAの配当利回りは？
INVENTIVA SAの配当利回りは0.00%です。
IVAの品質スコア（Quality Score）は？
当社のAIはIVAの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
IVAは今が買い時ですか？
当社AIのタイミングスコアは100点中50点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
IVAはどのセクターに属しますか？
INVENTIVA SAはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
IVA AI Analysis Summary
Our AI summary for IVA: INVENTIVA SA (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 2,290.08%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.48
Price
-0.14
(-3.03%)
Day Change
|
|
|---|
IVA, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROAが低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.48 |
| PBV / Sector |
-37.59 / 5.20
|
| Earning Per Share | -2.73 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
5.53 M
GREAT
|
| Average 1W Daily Value |
4.42 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:02 |
| Symbol | IVA |
| Name | INVENTIVA SA |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 236.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,091.34 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 50 rue de Dijon, Daix, France, 21121
Phone: 33 3 80 44 75 00
Website: https://inventivapharma.com
Employees: 69
Sector: Healthcare >> Biotechnology
Description: Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
